Pacira Pharm Inc (PCRX)

$23.98 -0.21 (-0.87%)
Market Cap 1.04B
Revenue (ttm) 700.97M
Net Income (ttm) -99.56M
EPS (ttm) N/A
PE Ratio 11.86
Forward PE 12.06
Profit Margin -14.20%
Debt to Equity Ratio 0.52
Volume 573,700
Avg Vol 639,322
Day's Range N/A - N/A
Shares Out 43.02M
Stochastic %K 67%
Beta 0.23
Analysts Sell
Price Target $30.17

Company Profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld c...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 813 553 6680
Address:
5401 West Kennedy Boulevard, Suite 890, Tampa, United States
AtomicAIerts
AtomicAIerts Dec. 5 at 10:09 AM
$PCRX AtomicAlerts Scalp Alert Direction: SHORT Entry: $23.99 TP1: $23.29 | TP2: $22.59 | TP3: $21.89 Stop Loss: $24.59 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 5 at 5:24 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PCRX Contract: Dec 19 $25C Entry: 0.65 Exit: 1.29 Return: +97.90% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 11:12 PM
1ightning® Premium Options Alert (Actionable) Ticker: $PCRX Contract: Dec 19 $25C Entry: 0.65 Exit: 1.29 Return: +97.90% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 6:52 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PCRX Contract: Dec 19 $20C Entry: 8.55 Exit: 13.78 Return: +61.21% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 3 at 3:26 PM
$PCRX's iovera system shows promise in facet-mediated CLBP treatment! Pilot study reveals iovera's cryoneurolysis outperforms RFA with significantly lower pain scores and reduced disability over 360 days. Plus, no treatment-related adverse events reported. Discover the full impact of these findings here 👉 https://www.zacks.com/stock/news/2798991/pcrxs-iovera-outperforms-rfa-therapy-in-pilot-study-for-low-back-pain?cid=sm-stocktwits-2-2798991-body-23249&ADID=SYND_STOCKTWITS_TWEET_2_2798991_BODY_23249
0 · Reply
ZacksResearch
ZacksResearch Dec. 3 at 2:26 PM
Game-changer alert for $PCRX Iovera just posted stronger, longer-lasting relief than RFA in a pilot CLBP study — and that tissue-sparing angle could be a real edge in spine care. See what this could mean for the future of pain management 👉 https://www.zacks.com/stock/news/2798991/pcrxs-iovera-outperforms-rfa-therapy-in-pilot-study-for-low-back-pain?cid=sm-stocktwits-2-2798991-teaser-23248&ADID=SYND_STOCKTWITS_TWEET_2_2798991_TEASER_23248
0 · Reply
Iightning
Iightning Dec. 3 at 10:20 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PCRX Contract: Dec 19 $20C Entry: 8.55 Exit: 16.53 Return: +93.33% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 1:12 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $PCRX **Contract:** Dec 19 $25C **Entry:** 0.89 **Exit:** 1.54 **Return:** **+74.09% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Iightning
Iightning Nov. 26 at 4:05 AM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.00 Exit: $1.40 | Profit: 39.87% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 2:12 PM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.00 Exit: $1.40 | Profit: 39.87% ROI | https://1ightning.com
0 · Reply
Latest News on PCRX
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 8:00 AM EST - 1 day ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

Nov 26, 2025, 4:01 PM EST - 8 days ago

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Nov 11, 2025, 8:00 AM EST - 23 days ago

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

Nov 10, 2025, 8:09 PM EST - 24 days ago

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 6:16 AM EST - 4 weeks ago

Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

Nov 6, 2025, 4:01 PM EST - 4 weeks ago

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Nov 5, 2025, 8:00 AM EST - 4 weeks ago

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

Nov 4, 2025, 7:00 AM EST - 4 weeks ago

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

Oct 30, 2025, 8:00 AM EDT - 5 weeks ago

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

Oct 27, 2025, 8:00 AM EDT - 5 weeks ago

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

Oct 23, 2025, 8:00 AM EDT - 6 weeks ago

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

Oct 21, 2025, 8:30 AM EDT - 6 weeks ago

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

Oct 20, 2025, 4:01 PM EDT - 6 weeks ago

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

Pacira (PCRX) Q2 Revenue Rises 1.7%

Aug 6, 2025, 6:12 AM EDT - 4 months ago

Pacira (PCRX) Q2 Revenue Rises 1.7%

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 2:42 AM EDT - 4 months ago

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

Pacira BioSciences Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:00 PM EDT - 4 months ago

Pacira BioSciences Reports Second Quarter 2025 Financial Results

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025

Jul 24, 2025, 8:00 AM EDT - 4 months ago

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025

Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit

Jul 16, 2025, 8:40 AM EDT - 5 months ago

Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation

Jun 17, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect

Jun 15, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation

Jun 12, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 6 months ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect

Jun 5, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 6 months ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

May 25, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out

May 22, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 20, 2025, 10:00 AM EDT - 7 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

May 18, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect

May 15, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect

Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation

May 13, 2025, 10:35 AM EDT - 7 months ago

Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out

May 13, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation

Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:31 PM EDT - 7 months ago

Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

Pacira BioSciences Reports First Quarter 2025 Financial Results

May 8, 2025, 4:00 PM EDT - 7 months ago

Pacira BioSciences Reports First Quarter 2025 Financial Results

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 8, 2025, 10:00 AM EDT - 7 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect

May 6, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation

May 4, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

May 2, 2025, 8:00 AM EDT - 7 months ago

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 1, 2025, 10:00 AM EDT - 7 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation

Apr 29, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Apr 29, 2025, 8:00 AM EDT - 7 months ago

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Reach Out

Apr 24, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Reach Out

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

Apr 22, 2025, 4:01 PM EDT - 8 months ago

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Reach Out

Apr 22, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Reach Out

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

Apr 21, 2025, 8:15 AM EDT - 8 months ago

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

AtomicAIerts
AtomicAIerts Dec. 5 at 10:09 AM
$PCRX AtomicAlerts Scalp Alert Direction: SHORT Entry: $23.99 TP1: $23.29 | TP2: $22.59 | TP3: $21.89 Stop Loss: $24.59 👉 https://atomicalerts.com
0 · Reply
Iightning
Iightning Dec. 5 at 5:24 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PCRX Contract: Dec 19 $25C Entry: 0.65 Exit: 1.29 Return: +97.90% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 11:12 PM
1ightning® Premium Options Alert (Actionable) Ticker: $PCRX Contract: Dec 19 $25C Entry: 0.65 Exit: 1.29 Return: +97.90% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 6:52 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PCRX Contract: Dec 19 $20C Entry: 8.55 Exit: 13.78 Return: +61.21% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 3 at 3:26 PM
$PCRX's iovera system shows promise in facet-mediated CLBP treatment! Pilot study reveals iovera's cryoneurolysis outperforms RFA with significantly lower pain scores and reduced disability over 360 days. Plus, no treatment-related adverse events reported. Discover the full impact of these findings here 👉 https://www.zacks.com/stock/news/2798991/pcrxs-iovera-outperforms-rfa-therapy-in-pilot-study-for-low-back-pain?cid=sm-stocktwits-2-2798991-body-23249&ADID=SYND_STOCKTWITS_TWEET_2_2798991_BODY_23249
0 · Reply
ZacksResearch
ZacksResearch Dec. 3 at 2:26 PM
Game-changer alert for $PCRX Iovera just posted stronger, longer-lasting relief than RFA in a pilot CLBP study — and that tissue-sparing angle could be a real edge in spine care. See what this could mean for the future of pain management 👉 https://www.zacks.com/stock/news/2798991/pcrxs-iovera-outperforms-rfa-therapy-in-pilot-study-for-low-back-pain?cid=sm-stocktwits-2-2798991-teaser-23248&ADID=SYND_STOCKTWITS_TWEET_2_2798991_TEASER_23248
0 · Reply
Iightning
Iightning Dec. 3 at 10:20 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PCRX Contract: Dec 19 $20C Entry: 8.55 Exit: 16.53 Return: +93.33% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 2 at 1:12 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $PCRX **Contract:** Dec 19 $25C **Entry:** 0.89 **Exit:** 1.54 **Return:** **+74.09% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Iightning
Iightning Nov. 26 at 4:05 AM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.00 Exit: $1.40 | Profit: 39.87% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 2:12 PM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.00 Exit: $1.40 | Profit: 39.87% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 3:04 AM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.00 Exit: $1.40 | Profit: 39.87% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 22 at 12:19 AM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.07 Exit: $1.52 | Profit: 41.55% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 3:39 AM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.07 Exit: $1.52 | Profit: 41.55% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 1:06 AM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.07 Exit: $1.52 | Profit: 41.55% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 9:16 AM
1ightning® Options Trade Alert (Actionable) | Buy $PCRX Dec 19 $25 Call | Enter: $1.07 Exit: $1.52 | Profit: 41.55% ROI | https://1ightning.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 17 at 11:50 AM
HC Wainwright & Co. has adjusted their stance on Pacira BioSciences ( $PCRX ), setting the rating to Buy with a target price of 38.
0 · Reply
GoldKing23
GoldKing23 Nov. 11 at 9:41 PM
$PCRX sounding very similar to when Sanofi acquired Genzyme in a $20.1 billion deal announced in February 2011 following about 7 months of public discussions and negotiations after sale rumors surfaced in mid-2010. The acquisition paid $74 per share plus contingent value rights (CVRs) to Genzyme shareholders. https://seekingalpha.com/news/4519996-pacira-biosciences-gains-as-investor-calls-for-full-sales-process?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 4:52 PM
Truist Securities has adjusted their stance on Pacira BioSciences ( $PCRX ), setting the rating to Buy with a target price of 30 → 28.
0 · Reply
Maestro60
Maestro60 Nov. 7 at 3:00 PM
$PCRX +8% good day after earnings
0 · Reply
d_risk
d_risk Nov. 7 at 12:14 AM
$PCRX - Pacira BioSciences Inc. Common Stock - 10Q - Updated Risk Factors PCRX warns its pMVL product patents cover only specific formulations and uses, not the active ingredients, leaving market share vulnerable to competitors with alternative delivery technologies. #Pharmaceuticals #DrugDeliveryTechnology #MarketCompetition #PatentRisk 🟢 Added 🟠 Removed https://d-risk.ai/PCRX/10-Q/2025-11-06
0 · Reply
A_Train1
A_Train1 Nov. 6 at 11:57 PM
$PCRX terrible - just terrible
0 · Reply
DonCorleone77
DonCorleone77 Nov. 6 at 9:37 PM
$PCRX Pacira reports Q3 EPS 70c, consensus 65c -- Q3 revenue $179.52M, consensus $182.33M. -- Cuts FY25 revenue view to $725M-$735M from $730M-$750M, consensus $737.15M. -- Raises FY25 gross margin view to 80%-82% from 78%-80%.
0 · Reply